Bayer Proposes Landmark Settlement to Resolve Roundup Litigation

Bayer PK US0727303028

In a decisive move aimed at drawing a line under years of legal uncertainty, Bayer has put forward a comprehensive settlement proposal potentially worth up to $10.5 billion to resolve U.S. litigation surrounding its glyphosate-based weedkiller, Roundup. The announcement, made yesterday, outlines a strategy to manage tens of thousands of current and future claims. The critical question for investors is whether this plan can finally deliver a permanent resolution.

The financial weight of the proposed settlement is substantial. Bayer confirmed in an ad-hoc release that its provisions for legal risks have been increased from ?7.8 billion to a total of ?11.8 billion. A significant portion of this, ?9.6 billion, is allocated specifically for the glyphosate disputes.

For the 2026 fiscal year, management anticipates settlement payments of approximately ?5 billion. These substantial outlays are expected to result in a negative free cash flow for that year. To ensure sufficient liquidity, the company has secured an $8 billion credit facility from a banking consortium. Consequently, the publication of the 2025 annual report and the 2026 outlook has been postponed from late February to March 4.

The Structure of the Proposed Resolution

The company's strategy rests on two main pillars. The first involves a class action settlement in St. Louis valued at $7.25 billion. This mechanism is designed to address both pending and potential future claims over a period of up to 21 years, aiming to provide a solution for about 65,000 current cases as well as future plaintiffs alleging health issues from glyphosate-containing products.

Separately, Bayer has agreed to individual settlements amounting to at least $3 billion. These funds are intended to conclude ongoing proceedings, including a significant judgment from the state of Georgia.

Market Response and Pending Legal Catalyst

Investors welcomed the prospect of bringing predictability to the long-running legal saga. In European trading yesterday, Bayer shares advanced by as much as 8.4 percent, approaching the ?50 mark.

Despite this major settlement proposal, a key date on the U.S. legal calendar remains highly relevant. In April, the U.S. Supreme Court is scheduled to hear a review in a specific Roundup case. A ruling favorable to Bayer on the question of federal law preempting state regulations could further limit the company's liability risks going forward. The board will present detailed financial figures and the new forecast on March 4.

Key Data Points:
* Settlement Value: Up to $10.5 billion for current and future cases.
* Legal Provisions: Increased to a total of ?11.8 billion.
* Cash Flow Impact: Negative free cash flow projected for 2026 due to high payouts.
* Reporting Date: Annual report publication delayed to March 4.